AlbuRel is human normal albumin. Albumin is the most abundant protein in human plasma and is synthesized by the liver. Albumin is an effective plasma volume expander.
Among its multiple physiological role, it plays an essential part in generation of colloid oncotic pressure.
It is used for restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate.
In the U.S. the indications for which albumin therapy are considered include hypovolemia or shock, burns, hypoalbuminemia, surgery or trauma, cardio pulmonary bypass, acute respiratory distress syndrome, hemodialysis and sequestration of protein rich fluid.
AlbuRel is available in 20percent, 5 percent concentrations in 100 ml and 50 ml pack sizes.
ImmunoRel is a solvent detergent treated, sterile preparation of chromatographically purified immunoglobulin G(IgG) derived from pooled human plasma.
IVIg therapy is used to provide antibodies to patients to prevent or treat some illnesses that can occur when the body does not produce enough of its own immunity to prevent these diseases.
The USFDA approved indications include Primary Immunodeficiency, ITP, Kawasaki disease, CLL, paediatric HIV infection, bone marrow transplantation (allogenic).
The off-label uses include GB syndrome, Multifocal Motor Neuropathy, CIDP, Lambert Eaton Myasthenic syndrome, Myasthenia Gravis, Neonatal Sepsis, Polymyositis, Dermatomyositis.
The normal immunoglobulin is meant for intravenous use. ImmunoRelis available in 5 percent concentrations in 100 ml and 50 ml pack sizes.
ReliSeal is biological glue and hemostatic agent, which can be used in a variety of surgical procedures to arrest bleeding, seal tissues and as an adjunct to wound healing.
A quick acting surgical fibrin sealant derived from human blood plasma, with hemostatic sealing and adhesive properties, ReliSeal mimics the final stage of the natural clotting mechanism. The kit is available in 1 ml pack size.
HemoRel A is a 250 IU preparation of clotting factor VIII. HemoRel A is indicated for replacement of factor VIII in patients, who have factor VIII deficiency i.e. patients diagnosed with haemophilia A. Factor VIII replacement is the therapy of choice for clotting disorder in haemophilia A.
HemoRel A is an intermediate pure factor VIII. It contains vWF ( 325 IU) and fibrinogen (35-55 percent of total protein). Intermediate pure factor VIII (plasma derived) is three fold less likely to give rise to inhibitors compared to recombinant products and can be used for vWF disease.
The product pack is user-friendly and includes one 20 ml syringe, two needles, water for injection, syringe filter and spirit swab.
ReliFeron belongs to the class of interferons (IFNs) which are natural proteins produced by the cells of the immune system in response to foreign agents such as viruses, bacteria, parasites and tumor cells.
Interferons are produced in body primarily from leukocyte, fibroblast and immune cell and the important ones are Interferons assist the immune response by activating natural killer cells and macrophages, promoting antigen presentation to lymphocytes and thus inducing the resistance of host cells against foreign agents. Interferons also have direct anti-viral effects.
Recombinant IFN-a is now approved worldwide in over 40 countries for the treatment of more than 14 malignancies and viral diseases, including adjuvant therapy in metastatic melanoma, condyloma acuminata, Kaposi's sarcoma and most importantly hepatitis B and C. Interferon-a has been shown to be effective in suppressing viral replication and in inducing remission of liver disease caused by chronic hepatitis B and hepatitis C virus infection.
ReliFeronis a purified sterile human recombinant interferon product classified as an alpha interferon. It has 165 amino acids, with a molecular weight of 19 kDa. ReliFeron is obtained by recombinant technology using Escherichia coli with an interferon alpha 2b gene from human leukocytes. It is used in the form of parenteral injection.
Each vial of ReliFeroncontains 3 or 5 million IU recombinant human interferon alpha 2b in 0.5 mL of aqueous buffer.
ReliGrast is human recombinant Granulocyte Colony Stimulating Factor (G-CSF), which is a specific growth factor known to stimulate production of neutrophils, a type of white blood cells in the body that are essential for fighting infections. It is active during the normal course of hematopoiesis and the hematopoietic stem cells get differentiated into white blood cells in the presence of G-CSF.
G-CSF is a protein having 175 amino acids, and has no glycosylation. E.coli is used for commercial manufacturing of recombinant G-CSF as a biosimilar. ReliGrast can be therapeutically used for reversing neutropenic conditions due to various reasons. It can be used in chemotherapy induced neutropenia, AIDS-associated neutropenia, congenital, cyclic idiopathic neutropenia. In the clinical trials conducted, ReliGrast has demonstrated efficacy in reducing the duration of Neutropenia (compared to 9 days) and recovery after ANC Nadir. The reduction in the incidence of Febrile Neutropenia, Grade 4 Neutropenia and Infection is also significant.
ReliGrastis available in the strength of 300 mcg/0.5 ml, as a pre-filled syringe.
Temozolomide is a prodrug, orally administered alkylating agent of the imidazotetrazine class, rapidly and completely absorbed and, at physiological pH, spontaneously hydrolyzed into the active metabolite.
Temozolomide capsules are indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. Temozolomide capsules are indicated for the treatment of adult patients with refractory anaplastic astrocytoma, i.e. patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine.
ReliNethra is the first stem cell-based therapy in the country. It is an autologous limbal stem cell composite graft, prepared from the limbal biopsy excised from the healthy eye of the patient.
ReliNethra comprises of limbal epithelial stem cells cultured ex vivo on human amniotic membrane (HAM).
Cellular Component: Limbal epithelial cells
Matrix Component: Basement membrane of HAM
It is a 4 cm2 denuded human amniotic membrane with cultured autologous limbal biopsy explants with 80 percent of the cells positive for p63 marker.
ReliNethraLimbal transplant leads to renewal of ocular surface epithelial cells thereby replacing the damaged ocular surface with smooth and healthy cells. Limbal stem cell transplant results in re-epithelialization of the reconstructed corneal surface. Continuous centripetal movement of cultured corneal epithelium on the human amniotic membrane towards the visual axis treats the damaged ocular surface by smooth reconstruction.
ReliNethra Transplant is indicated in unilateral partial and total limbal stem cell deficiency conditions like:
- Chemical burns
- Thermal burns
- Mechanical injuries to cornea
- Ionizing radiation injuries
- Multiple surgical procedures or cryotherapies affecting the limbal region
- Contact lens-induced keratopathy
- Severe microbial keratitis
- Stevens-Johnson syndrome
The protocol of the product includes Agreement with the doctor, informed consent of the patient, planning for limbal biopsy of the same patient, processing into the ReliNethragraft and planning the transplantation in the affected eye.
ReliHeal - G is a single use sterile gauze supported hydrogel wound dressing ReliHeal - G is a type of occlusive dressing that provides a moist environment to the wound bed.
The moisture-retentive occlusive dressings of ReliHeal - G promote migration of new epidermal cells across the wound surface and are beneficial for early wound healing.
Added benefits include decreased infection rates, autolytic debridement of slough and necrotic tissue and minimal pain or trauma to the wound bed, when it is applied or removed.
ReliHeal - G dressing is intended to be used as a primary dressing in the management of partial and full-thickness wounds, including diabetic ulcers, venous stasis ulcers, pressure ulcers, surgical wounds, ischemic ulcers, traumatic wounds, superficial burns, donor sites, abrasions and lacerations.
Relix is a range of Molecular diagnostic and Genetic testing services offered by Reliance Life Sciences for diagnosing several infectious diseases and genetic disorders.
- Human Immunodeficiency Virus
- Hepatitis B Virus
- Hepatitis C Virus
- Dengue Virus
- Japanese Encephalitis Virus
- Parvovirus B19
- Mycoplasma Pneumoniae
- Neisseria Gonorrhoeae
- Human Papilloma Virus
- B K Virus
- Hepatitis B Virus
- Hepatitis C Virus
- Bcr/ abl
- B K Virus
Genotyping (Sequencing based tests)
- Hepatitis C Virus
- Hepatitis B Virus
- Human Leukocyte Antigen (HLA) Typing
- K Ras Mutation test
- EGFR Mutation test
- Warfarine drug resistance test
- HBV Drug resistance test
- Karyotyping of Peripheral blood cells
- Karyotyping of bone marrow
- Fragile X & Y detection
- Chromosome breakage studies
- Cord blood karyotyping
- Amniotic fluid karyotyping
- CVS karyotyping
Fluorescence In-Situ Hybridization (FISH)
- Aneuploidy detection
- Microdeletion detection
- Oncology: quantitative analysis
- BRCA1/BRCA2 for familial breast cancer
- Medullar Thyroid Carcinoma
- CVD Risk marker test
To,Reliance Life Science